|
1
|
Tong AW and Nemunaitis J: Modulation of
miRNA activity in human cancer: A new paradigm for cancer gene
therapy? Cancer Gene Ther. 15:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu Z, Jian Z, Shen SH, Purisima E and Wang
E: Global analysis of microRNA target gene expression reveals that
miRNA targets are lower expressed in mature mouse and
Drosophila tissues than in the embryos. Nucleic Acids Res.
35:152–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steffens S, Roos FC, Janssen M, Becker F,
Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thüroff
JW, et al: German Renal Cell Cancer Network: Clinical behavior of
chromophobe renal cell carcinoma is less aggressive than that of
clear cell renal cell carcinoma, independent of Fuhrman grade or
tumor size. Virchows Arch. 465:439–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Doehn C, Witzsch U and Siebels M: Active
surveillance for renal cell carcinoma. Aktuelle Urol. 43:243–249.
2012.(In German). PubMed/NCBI
|
|
5
|
Chen T, Fallah M, Sundquist K, Liu H and
Hemminki K: Risk of subsequent cancers in renal cell carcinoma
survivors with a family history. Eur J Cancer. 50:2108–2118. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hew MN, Zonneveld R, Kümmerlin IP, Opondo
D, de la Rosette JJ and Laguna MP: Age and gender related
differences in renal cell carcinoma in a European cohort. J Urol.
188:33–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cairns P: Renal cell carcinoma. Cancer
Biomark. 9:461–473. 2010.PubMed/NCBI
|
|
8
|
Olshan AF, Kuo TM, Meyer AM, Nielsen ME,
Purdue MP and Rathmell WK: Racial difference in histologic subtype
of renal cell carcinoma. Cancer Med. 2:744–749. 2013.PubMed/NCBI
|
|
9
|
Banyra O, Tarchynets M and Shulyak A:
Renal cell carcinoma: How to hit the targets? Cent European J Urol.
66:394–404. 2014.PubMed/NCBI
|
|
10
|
Ngo TC, Wood CG and Karam JA: Biomarkers
of renal cell carcinoma. Urol Oncol. 32:243–251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
White NM, Khella HW, Grigull J, Adzovic S,
Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA,
et al: miRNA profiling in metastatic renal cell carcinoma reveals a
tumor-suppressor effect for miR-215. Br J Cancer. 105:1741–1749.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beresneva EV, Rykov SV, Hodyrev DS,
Pronina IV, Ermilova VD, Kazubskaia TP, Braga EA and Loginov VI:
Methylation profile of group of miRNA genes in clear cell renal
cell carcinoma; involvement in cancer progression. Genetika.
49:366–375. 2013.(In Russian). PubMed/NCBI
|
|
13
|
Mei Q, Li X, Guo M, Fu X and Han W: The
miRNA network: Micro-regulator of cell signaling in cancer. Expert
Rev Anticancer Ther. 14:1515–1527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Filip A: MiRNA - new mechanisms of gene
expression control. Postepy Biochem. 53:413–419. 2007.(In Polish).
PubMed/NCBI
|
|
15
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giannakakis A, Coukos G, Hatzigeorgiou A,
Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human
cancers. Expert Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mezzanzanica D, Canevari S, Cecco LD and
Bagnoli M: miRNA control of apoptotic programs: Focus on ovarian
cancer. Expert Rev Mol Diagn. 11:277–286. 2011.PubMed/NCBI
|
|
18
|
Rose AJ, Alsted TJ, Jensen TE, Kobberø JB,
Maarbjerg SJ, Jensen J and Richter EA: A
Ca(2+)-calmodulin-eEF2K-eEF2 signalling cascade, but not
AMPK, contributes to the suppression of skeletal muscle protein
synthesis during contractions. J Physiol. 587:1547–1563. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu LL, Xie T, Zhang SY and Liu B:
Eukaryotic elongation factor-2 kinase (eEF2K): A potential
therapeutic target in cancer. Apoptosis. 19:1527–1531. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arora S, Yang JM, Kinzy TG, Utsumi R,
Okamoto T, Kitayama T, Ortiz PA and Hait WN: Identification and
characterization of an inhibitor of eukaryotic elongation factor 2
kinase against human cancer cell lines. Cancer Res. 63:6894–6899.
2003.PubMed/NCBI
|
|
21
|
Xie CM, Liu XY, Sham KW, Lai JM and Cheng
CH: Silencing of EEF2K (eukaryotic elongation factor-2 kinase)
reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
Autophagy. 10:1495–1508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu H, Yang X, Liu J, Zhou L, Zhang C, Xu
L, Qin Q, Zhan L, Lu J, Cheng H and Sun X: Eukaryotic elongation
factor 2 kinase confers tolerance to stress conditions in cancer
cells. Cell Stress Chaperones. 20:217–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B, Cheng Y, Liu Q, Bao JK and Yang M:
Autophagic pathways as new targets for cancer drug development.
Acta Pharmacol Sin. 31:1154–1164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tekedereli I, Alpay SN, Tavares CD,
Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby
KN and Ozpolat B: Targeted silencing of elongation factor 2 kinase
suppresses growth and sensitizes tumors to doxorubicin in an
orthotopic model of breast cancer. PLoS One. 7:e411712012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y, Zhu X, Zhang X, Liu B and Huang L:
Nanoparticles modified with tumor-targeting scFv deliver siRNA and
miRNA for cancer therapy. Mol Ther. 18:1650–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qi M, Huang X, Zhou L and Zhang J:
Identification of differentially expressed microRNAs in metastatic
melanoma using next-generation sequencing technology. Int J Mol
Med. 33:1117–1121. 2014.PubMed/NCBI
|
|
27
|
Kruger NJ: The Bradford method for protein
quantitation. Basic Protein and Peptide Protocols. Walker JM:
32:(Totowa, NJ). Humana Press. 9–15. 1994. View Article : Google Scholar
|
|
28
|
Creel PA: Optimizing patient adherence to
targeted therapies in renal cell carcinoma. Clin J Oncol Nurs.
18:694–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen C, Ai H, Ren J, Li W, Li P, Qiao R,
Ouyang J, Yang M, Ma J and Huang L: A global view of porcine
transcriptome in three tissues from a full-sib pair with extreme
phenotypes in growth and fat deposition by paired-end RNA
sequencing. BMC Genomics. 12:4482011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lyons PJ, Lang-Ouellette D and Morin P Jr:
CryomiRs: Towards the identification of a cold-associated family of
microRNAs. Comp Biochem Physiol Part D Genomics Proteomics.
8:358–364. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: A new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang Y, Dai Y, Yang J, Chen T, Yin Y,
Tang M, Hu C and Zhang L: Microarray analysis of microRNA
expression in renal clear cell carcinoma. Eur J Surg Oncol.
35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang H, Guo Y, Shang C, Song Y and Wu B:
miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer.
Urology. 80:1298–1302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Knebel A, Haydon CE, Morrice N and Cohen
P: Stress-induced regulation of eukaryotic elongation factor 2
kinase by SB 203580-sensitive and -insensitive pathways. Biochem J.
367:525–532. 2002. View Article : Google Scholar : PubMed/NCBI
|
